


CIG Pannonia

Recommendation: BUY (unch.)

Target price (e-o-y): HUF 410 (unch.)

Share price: HUF 260

Share price as of 31/05/2023	HUF 260
Number of diluted shares [million]	94.4
Market capitalization [HUF mn/EUR mn]	25 023 / 67.5
Daily turnover 12M [HUF million]	0.01
Bloomberg	PANNONIA HB
Reuters	CIGP.BU
Free float	44.7%
52 week range	HUF 220 – 318



Adjusted net results under IFRS 17 grew threefold YoY in Q1/23

Equity Analyst

Attila Vágó

+361 489 2265

a.vago@con.hu

Alkotás Point

55-61 Alkotás utca,


H-1123 Budapest

www.con.hu

- CIG Pannonia (Pannonia) reported its first quarter results for the first time in accordance with IFRS 17 standards, which significantly differ from the results reported according to IFRS 4 standards used in the market until now. The introduction of the IFRS 17 accounting transition methodology for 31 December 2021 resulted in a significant increase of HUF 7.3bn (+56%) from HUF 13.2bn to HUF 18.7bn in Pannonia's consolidated equity at that date, implying a BVPS of HUF 198 and 1.3x P/BV. However, the application of the IFRS 17 standard also meant a tax burden of HUF 475mn, which is charged to the result of the first quarter of 2023. Also importantly, according to the IFRS 17 methodology, Pannonia's consolidated after-tax profit for the entire year of 2022 was finally ca. HUF 199mn higher (HUF 1.41bn) than under the IFRS 4 standards.
- Consolidated after tax for Q1/23 was a loss of HUF 382mn compared to HUF 28mn in Q1/22. The primary reason for the loss is the aforementioned one-off tax charge of HUF 475mn due to the capital gain from the transition to IFRS 17 accounting standards. Adjusting for this tax effect, the profit after tax was HUF 93 million, which is actually three times the net profit in the first quarter of last year. From now on, the best approach to understand what HUF 93mn was made of is not the gross accounting of income and expenses, but the change in the result of the product groups presented according to the new IFRS 17 financial standards applied for insurance carriers compared to the same period of the previous year. Accordingly, the insurance portfolios are evaluated using the so-called General Measurement Model (GMM), the Premium Allocation Approach (PAA) and the Variable Fee Approach (VFA).
- It is important to emphasize that from now on, the recorded written amount of premium income is determined not by premium income and their time-proportional part (this was a kind of "gross approach" until now), but by the insurance services provided (from now on according to a kind of "net approach"), ie. the insurance profit achieved on insurance products according to IFRS 17 is continuously released during the life of the given product (the scope of the contract), according to the level

of services undertaken and not as time goes by. The role of future expectations and their changes has become very important: the insurer must have a forecast for service levels and expected cash flows for each group of contracts (GIC: Group of Insurance Contracts). The newly reported result is actually the difference between the calculated and expected performance at the time of the creation of the GIC, and the actual performance calculated later, with the inclusion of a previously unused risk measure (risk adjustment), the financial effect of which is that the insurance company creates a reserve (which it subsequently releases gradually). Separate evaluation methodologies apply to product groups, including UL-insurance products, the investment premium part of which will no longer appear in income and expenses, only that part of them which belong to the insurer.

- As for the breakdown of the increase of the consolidated results before taxes according to IFRS 17:



Source: Pannonia

- GMM life products:** HUF 33mn loss YoY due mainly to traditional and term life insurances. The loss on the credit insurance policies taken over from the insurance company BNP Paribas Cardif was significantly mitigated by the volume and profit growth of group life and accident insurances, as well as the volume growth of risk life insurances.
- GMM non-life:** HUF 147mn increase in profit explained by the fact that the loss reserve for Italian surety products (LIC, i.e. Liability for Incurred Claims) expressed in HUF decreased due to the strengthening of the HUF. The further improvement was caused by the increase in the effectiveness of engineering insurance.
- PAA life products:** HUF 130mn increase in profit YoY achieved in short-term life, accident and health insurance as a result of the lower loss ratio assumptions for group life and accident insurance, while the insurance company's portfolio through MVM has expanded, and the results of group service financing insurance packages have also improved primarily thanks to the updated Elixir product.
- PAA non-life:** HUF 163mn decrease in profit which was attributable to two products, fleet Casco and industrial property insurance in case of which Pannonia has not yet reached economics of scale, premiums are not yet enough to offset the related costs. However, Pannonia's mid-term strategy has already taken into account this effect in the initial phase of business expansion.

Outlook

- We reiterate CIG Pannonia (Pannonia) as BUY, as well as our 12-m target price at HUF 410, which leaves a 58% upside potential from the current share price.
- We leave our net income forecasts for 2023 and 2024 unchanged at HUF 1.56bn and HUF 2.04bn, respectively, which reflect the harmful impact of 1) a substantial increase in insurance (“windfall”) tax imposed on Hungarian insurers for the period between 1 July 2022 and 31 December, 2024, and 2) slowdown in economic growth as a consequence of high inflation eroding household real incomes and a great deal of uncertainty amid tightening financial conditions. Consequently, EPS may come in at HUF 17 in 2023 and then to grow again by 31% to HUF 22 in 2024.
- We remain confident that Pannonia's resilient and flexible organization can weather the impending economic slowdown, rather than being overwhelmed by it, while remaining committed to market expansion and product innovation.

Disclaimer

Concorde Securities Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interests that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For analysts' certification and other important disclosures, please refer to the "Disclaimer" section at the end of this report.

DISCLAIMER I.

This research report has been prepared by Concorde Securities Ltd., a full-service Hungarian investment banking, investment management and brokerage firm. Concorde Securities Ltd. is under the supervision of the National Bank of Hungary in its capacity as financial supervisory authority.

Concorde Securities Ltd. is registered in Hungary and does not have any subsidiaries, branches or offices outside of Hungary. Therefore we are not allowed to provide direct investment banking services to US investors and restrictions may apply to our potential investment banking services according to your country's jurisdiction.

Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are their own and may be contrary to the opinions expressed in our research products, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed by our analysts or traders.

Our research, sales and trading professionals are paid based on the profitability of the respective divisions of Concorde Securities Ltd., which from time-to-time may include revenues from the firm's capital market activity. Concorde Securities Ltd. does not prohibit analysts, salespeople and traders from maintaining a financial interest in the securities or futures of any companies that they cover or trade on their clients' behalf in strict compliance with the Hungarian Capital Markets Act.

ANALYSTS CERTIFICATION

The research analysts undersigned and responsible for the preparation of this report hereby certify that (i) the views expressed in this research report accurately reflect their personal views about any and all of the securities or issuers referred to in this research report; (ii) no part of the analysts' compensation was, is or will be directly or indirectly related to the specific recommendation or views expressed in this report and (iii) no part of their compensation is tied to any specific investment transactions performed by Concorde Securities Ltd.

Name and job title of individuals involved in the production of this report are disclosed at the end of this report.

Concorde Securities Ltd. is a leading manager and underwriter of Hungarian equity offerings. We have investment banking and other business relations with a substantial percentage of the companies traded on the Budapest Stock Exchange and covered by our research department. Concorde Securities Ltd, its directors and employees may have a position in these securities, which may change at any time.

Concorde Securities Ltd. acted as Lead Manager of the private and public share placement of the shares of FHB in 2003, Masterplast in 2012 and Duna House in 2016. Concorde Securities Ltd. acted as the Co-lead Manager of Gedeon Richter's exchangeable bond issue in September 2004. Concorde Securities Ltd. has provided financial advice to Magyar Telekom.

EXPLANATION OF RATINGS AND METHODOLOGY

Rating	Trigger
Buy	Total return is expected to exceed 20% in the next 12 months
Accumulate	Total return is expected to be in the range of 10-20%
Neutral	Total return is expected to be in the range of 10%-(-10%)
Reduce	Total return is expected to be in the range of -10-(-20%)
Sell	Total return is expected to be lower than -20%
Under Revision	The stock is put Under Revision if the covering analyst considers new information may change the valuation materially and if this may take more time.

Coverage in transition

Coverage in transition rating is assigned to a stock if there is a change in analyst.

Securities prices:

Prices are taken as of the previous day's close on the home market unless otherwise stated.

Valuations and risks:

Analysis of specific risks to set stock target prices highlighted in our investment case(s) are outlined throughout the report. For details of methodologies used to determine our price targets and risks related to the achievement of the targets referred to in the main body of the report or at [Rating Methodology](https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038) on our website, visit (https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038)

Research disclosures:

Concorde Securities Ltd. may have published other investment recommendations in respect of the same securities/instruments recommended in this report during the preceding 12 months. Disclosure of previous investment recommendations produced by Concorde Securities Ltd. in the previous 12 months can be found at [Rating history](https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038). (<https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038>)

GENERAL

This report is provided for information purposes only and does not represent an offer for sale, or the solicitation of any offer to buy or sell any securities.

The information, and any opinions, estimates and forecast have been obtained from sources believed by us to be reliable, but no representation or warranty, express or implied is made by us as to their accuracy or completeness. The information, opinions, estimates and forecasts may well be affected by subsequent changes in market conditions. This document may not be reproduced in whole or in part, or published for any purpose.

REPRODUCTION OR REBROADCAST OF ANY PORTION OF THIS RESEARCH REPORT IS STRICTLY PROHIBITED WITHOUT THE WRITTEN PERMISSION OF CONCORDE SECURITIES LTD.

DISCLAIMER II.

This research/commentary was prepared by the assignment of Budapest Stock Exchange Ltd. (registered seat: 1054 Budapest, Szabadság tér 7. Platina torony I. ép. IV. emelet; company registration number: 01-10-044764, hereinafter: BSE) under the agreement which was concluded by and between BSE and Concorde Securities Ltd. (registered seat: H-1123 Budapest Alkotás utca 50., company registration number: 01-10-043521, hereinafter: Investment Service Provider)

BSE shall not be liable for the content of this research/commentary, especially for the accuracy and completeness of the information therein and for the forecasts and conclusions; the Service Provider shall be solely liable for these. The Service Provider is entitled to all copyrights regarding this research/commentary however BSE is entitled to use and advertise/spread it but BSE shall not modify its content.

This research/commentary shall not be qualified as investment advice specified in Point 9 Section 4 (2) of Act No. CXXXVIII of 2007 on Investment Firms and Commodity Dealers and on the Regulations Governing their Activities. Furthermore, this document shall not be qualified as an offer or call to tenders for the purchase, sale or hold of the financial instrument(s) concerned by the research/commentary.